Description

Dusquetide (SGX942) is a first-in-class innate defense regulator (IDR). Dusquetide modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide shows activity in both reducing inflammation and increasing clearance of bacterial infection[1]. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)–COVID-19-immunoregulation–C25H47N9O5—-[1]Kudrimoti M, et al. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotechnol. 2016 Dec 10;239:115-125.–931395-42-5–553.70–99.10–C[C@@H](C(N)=O)NC([C@H]1N(C([C@H](C(C)C)NC([C@H]([C@@H](C)CC)NC([C@H](CCCNC(N)=N)N)=O)=O)=O)CCC1)=O–Cancer; Infection–H2O : 50 mg/mL (ultrasonic)–Bacterial;p62—-Anti-infection;Autophagy–Peptides